Chemical Compound

Mibefradil

CAS Registry Number 116644-53-2

Back to search Request a Quote

Primary Record

Mibefradil

In stock: 9,025 g
Purity: 99.6 %
CAS: 116644-53-2

Compound Identifiers & Properties

CAS: 116644-53-2
PubChem CID: 60663
SMILES: CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
Canonical SMILES: COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C

Names & Synonyms

Mibefradil
Posicor
Mibefradil dihydrochloride
Mibefradil HCl
mibefradilum
Mibefradil (INN)
Mibefradil [INN:BAN]
116644-53-2
Posicor 50
Posicor 100
AC1L1TOE
Lopac-M-5441
MIBEFRADIL [MI]
C29H38FN3O3
AC1Q4NDV
MIBEFRADIL [INN]
RefChem:925843
MIBEFRADIL [VANDF]
CHEMBL45816
D0W8XT
Mibefradil dihydrochloride hydrate
Ro 40-5967
MIBEFRADIL [WHO-DD]
Lopac0_000748
SCHEMBL39551
DTXSID1023318
UNII-27B90X776A
MLS001056800
HBNPJJILLOYFJU-VMPREFPWSA-N
MIBEFRADILDIHYDROCHLORIDE
CHEBI:6920
DTXCID403318
GTPL2522
orb1679032
27B90X776A
Ro 405967
SCHEMBL29359482
SCHEMBL29364574
SCHEMBL30170543
BDBM78934
C08CX01
cid_16746591
Ro 40 5967
116666-63-8 (anhydrous)
BCP09875
CID60663
ro40-5967
ZINC3782486
3847AH
BDBM50117922
C29-H38-F-N3-O3
NSC760798
AKOS022185482
CCG-204833
CS-1218
DB01388
NSC-760798
SDCCGSBI-0050726.P002
NCGC00015683-01
NCGC00161420-01
NCGC00161420-03
NCGC00161420-04
NCGC00161420-12
4CA-0818
AJ-45594
HY-15553
SC-51476
SMR000326970
J281.718G
LS-172325
NS00001714
Ro-405967-001
[(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate
C07222
D08217
W-5171
Acetic acid, methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester
Q6827783
BRD-K09549677-300-01-8
BRD-K09549677-300-03-4
Acetic acid, methoxy-, 2-(2-((3-(1H-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, (1S-cis)-
Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer)
(1S-cis)-2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate
2-(2-((3-(1H-Benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl methoxyacetate (1S-cis)-
(1S,2S)-(2-((3-(2-benzimidazolyl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl)(methyl)amino)ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
[(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl] 2-methoxyacetate
Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
((1S,2S)-2-(2-(3-(1H-benzimidazol-2-yl)propyl-methyl-amino)ethyl)-6-fluoro-1-isopropyl-tetralin-2-yl) 2-methoxyacetate
((1S,2S)-2-(2-(3-(1H-benzimidazol-2-yl)propyl-methylamino)ethyl)-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl) 2-methoxyacetate
(1S,2S)-2-(2-{[3-(1H-1,3-Benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
(1S,2S)-2-(2-{[3-(1H-1,3-benzodiazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
(1S,2S)-2-(2-{[3-(1H-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl (methyloxy)acetate
(1S,2S)-2-(2-{[3-(1H-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(propan-2-yl)-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
(1s,2s)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate
(1S,2S)-2-[2-{[3-(1H-benzimidazol-2-yl)propyl]-methylamino }ethyl]-6-fluoro- 1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
(1S,2S)-2-[2-{[3-(1H-benzimidazol-2-yl)propyl]-methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
(1S,2S)-2-[2-{[3-(1H-benzimidazol-2-yl)propyl]methylamino}ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate
[(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoranyl-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyethanoate;hydrate;hydrochloride
[(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] 2-methoxyacetate;hydrate;hydrochloride
2-{2-[3-(1H-benzoimidazol-2-yl)-propylamino]-ethyl}-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester(Mibefradil)Methoxy-acetic acid
2-methoxyacetic acid [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl] ester;hydrate;hydrochloride
2-methoxyacetic acid [(1S,2S)-2-[2-[3-(1H-benzimidazol-2-yl)propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl] ester;hydrate;hydrochloride
Acetic acid, 2-methoxy-, (1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenylester, hydrochloride (1:2)
Acetic acid, methoxy-,(1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenylester
Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
Methoxy-acetic acid (1S,2S)-2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester
Methoxy-acetic acid 2-(2-{[3-(1H-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-naphthalen-2-yl ester
Methoxyacetic acid [[(1S,2S)-2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropylnaphthalen]-2-yl] ester
Posicor Monohydrate; Ro 40-5967 Monohydrate; Methoxyacetic Acid (1S,2S)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Ester Dihydrochloride Monohydrate; Methoxyacetic Acid (1S-cis)-2-[2-[[3-(1H-Benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl Ester Dihydrochloride Monohydrate; Ro 40-5967/001 Monohydrate;